Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XOMA vs URGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XOMA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

XOMA Overall Winner 6-Pillar Tally: XOMA 3 – 2 URGN (1 Tie) Matrix Metrics: XOMA 5 – 5 URGN

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over UroGen Pharma Ltd. (URGN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas URGN carries 61.5/100 (BUY) at $28.41 (10.2x Forward P/E, -12.4% operating margin).

  • Composite vs. Pillar Nuance: While URGN currently prints a higher short-term Unified Composite Score (61.5/100 BUY vs. XOMA 55.8/100 HOLD), XOMA captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-3.9% vs. -12.4% operating margin) and revenue trajectory (-22.6% vs. +223.9% YoY).
  • Technical & Structure Timing Caution: XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5); meanwhile URGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XOMA vs URGN
XOMA NASDAQ Head-to-Head Winner
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
TTM Revenue $49M
Forward P/E 21.5x
Beta / 30D Vol 0.68β · 37% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06
URGN NASDAQ
UroGen Pharma Ltd. Ordinary Shares
Pharmaceutical Preparations
$28.41
+8.54% 1D
Market Cap $1.3B
TTM Revenue $250M
Forward P/E 10.2x
Beta / 30D Vol 1.33β · 82% Vol
Unified Composite Score
61.5 / 100 BUY
Tech 70.0 Fund 66.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.6%), weak momentum, RSI 37
RSI-14: 37.1 · SMA20: $30.72 · SMA50: $36.68

6-Pillar Scorecard Institutional Category Breakdown (XOMA 3 – 2 URGN)

Columns: Metric · XOMA · URGN
1. Valuation Multiples URGN
Forward P/E 21.5x 10.2x
Trailing P/E 28.2x 12.9x
PEG Ratio N/M N/M
EV / Revenue 16.1x 5.5x
2. Growth & Scale URGN
Revenue Growth (YoY) -22.6% +223.9%
Earnings Growth (YoY) +207.9% +0.0%
TTM Revenue (USD) $49M $250M
Market Cap $781.8M $1.3B
3. Profitability & Quality XOMA
Gross Margin 99.0% 91.4%
Operating Margin -3.9% -12.4%
Net Profit Margin 69.6% -26.3%
Return on Equity (ROE) 34.2% -1481.3%
4. Balance Sheet & Cash Flow XOMA
Cash Generation (TTM) $8.3M EBITDA -$132M
Cash Flow Margin 17.1% EBITDA Mgn -52.8%
Net Cash / Leverage $7.79 Book/Sh · 34.2% ROE $111M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XOMA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 101.5% (100th %ile) 112.8% (10th %ile)
Put/Call OI Skew N/A 0.13x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XOMA (5) vs URGN (5)
Institutional Metric XOMA URGN Criterion Row Edge
Market Capitalization
Scale
$781.8M $1.3B Larger Scale URGN
Trailing P/E Ratio
Valuation
28.2x 12.9x Lower Multiple URGN
Forward P/E Ratio
Valuation
21.5x 10.2x Lower Multiple URGN
Revenue Growth (YoY)
Growth
-22.6% +223.9% Higher Growth URGN
Operating Margin (TTM)
Profitability
-3.9% -12.4% Higher Margin XOMA
Net Profit Margin
Profitability
69.6% -26.3% Higher Margin XOMA
Return on Equity (ROE)
Capital Efficiency
34.2% -1481.3% Higher ROE XOMA
52-Week Range Position
Momentum
78% ($22–$45) 35% ($16–$51) Stronger Trend XOMA
Beta / 30D Volatility
Risk Regime
0.68β · 37% Vol 1.33β · 82% Vol Lower Realized Risk XOMA
Unified Institutional Score
Composite Signal
55.8 / 100 (HOLD) 61.5 / 100 (BUY) Higher Composite URGN
Trailing 12M Revenue (USD)
Operating Scale
$49M $250M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.0% 91.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.1x EV/Rev N/M PEG · 5.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE) -$132M ($111M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon URGN +44.92 pp
XOMA: -3.81% · URGN: +41.11%
3M Horizon URGN +73.83 pp
XOMA: +9.34% · URGN: +83.17%
6M Horizon URGN +34.08 pp
XOMA: +34.26% · URGN: +68.34%
1Y Horizon URGN +40.58 pp
XOMA: +24.6% · URGN: +65.18%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs URGN. Trailing 12-month operating profitability (XOMA -3.9% vs URGN -12.4%) and valuation multiples (XOMA 21.5x vs URGN 10.2x Forward P/E) are benchmarked directly in Pillar 4 below.

XOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin99.0%
Op. Margin-3.9%
ROE / Fwd P/E34.2% · 21.5x
URGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$250M
Gross Margin91.4%
Op. Margin-12.4%
ROE / Fwd P/E-1481.3% · 10.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XOMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 101.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
URGN BREAKDOWN
96d in phase · OBV DISTRIBUTION
Current IV 112.8%
IV Percentile 10th %ile
Put/Call OI Skew 0.13x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact URGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XOMA Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
URGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -12.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XOMA vs URGN Key Questions & Quantitative Answers

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over UroGen Pharma Ltd. (URGN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas URGN carries 61.5/100 (BUY) at $28.41 (10.2x Forward P/E, -12.4% operating margin). Composite vs. Pillar Nuance: While URGN currently prints a higher short-term Unified Composite Score (61.5/100 BUY vs. XOMA 55.8/100 HOLD), XOMA captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-3.9% vs. -12.4% operating margin) and revenue trajectory (-22.6% vs. +223.9% YoY). Technical & Structure Timing Caution: XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5); meanwhile URGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

URGN leads the Growth & Scale pillar: XOMA posts -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin), compared with URGN at +223.9% YoY revenue growth and +0.0% YoY earnings growth on $250M TTM revenue (91.4% gross margin, -12.4% operating margin). On trailing 12-month operating scale, XOMA generates $49M in USD-normalized revenue versus $250M for URGN. In operating R&D and SG&A reinvestment, XOMA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for URGN.

URGN screens cheaper on headline valuation multiples. XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin), whereas URGN trades at 10.2x Forward P/E, 12.9x Trailing P/E, N/M PEG, and 5.5x EV/Revenue (-52.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XOMA (34.2% ROE) versus URGN (-1481.3% ROE) capital efficiency.

In options market volatility and institutional positioning, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk). By comparison, URGN carries 112.8% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.33β · 82% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.